Codexis, Inc. completed a public offering of 16,666,677 shares of common stock at $1.50 per share, generating approximately $23.1 million in net proceeds. The offering was underwritten by Piper Sandler & Co. and Cantor Fitzgerald & Co. as representatives. Codexis, Inc. is a biotechnology company that develops enzyme-based solutions for industrial and pharmaceutical applications.

Codexis, Inc. expects to report at least $14.8 million in total revenue for the three months ended June 30, 2026, and approximately $54.9 million in cash, cash equivalents, and short-term investments for the same period. These figures are preliminary estimates based on management's reviews. Codexis, Inc. is a biotechnology company that develops enzyme-based solutions for industrial and pharmaceutical applications.